In the leukemia patient application, we focused specifically on the activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD), which are detected in approximately 20% of AML patients associated with a poor prognosis (Thiede et al., 2002). This evidence concerns the gene FLT3 and acute myeloid leukemia.